Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluorine-18 arachidonic acid is a radiolabeled analog of the polyunsaturated fatty acid arachidonic acid, developed as a positron emission tomography (PET) imaging agent. It serves as a metabolic tracer to study lipid signaling and metabolism, particularly the activity of phospholipase A2 (PLA2) enzymes, which release arachidonic acid from membrane phospholipids. In the context of oncology, specifically advanced prostate cancer, its uptake is used to visualize metabolic reprogramming driven by oncogenes like MYC and epigenetic regulators like KMT2A. The tracer is also utilized in neuroimaging to investigate neuroinflammation and brain signaling, where arachidonic acid metabolism is a key component of the inflammatory response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorine-18 arachidonic acid.